Pharma dealmaking slowed in early 2026 as buyers tightened valuation discipline and increased diligence across life sciences transactions. AI partnerships, manufacturing acquisitions, and oncology consolidation are shaping the next phase of pharma deal activity, with recovery expected in late 2026
